共 14 条
[1]
Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Russell RE,Culpitt SV,DeMatos C,et al. Am J Respir Cell Mol Biol . 2002
[2]
Combined sameterol and fluticasone in the treatment of chronic obstructive pulmonary disease:a randomized controlled trial. Calverley P M,Pauwel RA,Vestbol,et al. The Lancet . 2003
[3]
Inhaled combination therapy with long-actingβ 2-agonists and corticoeteroids in stable COPD. Cazzola M,Dahl R. Chest . 2004
[4]
Mechanisms in COPD: differences from asthma. Barnes PJ. Chest . 2000
[5]
Macrolides for the treatment of chronic sinusitis,asthma,and COPD. Mark H Gotfried. Chest . 2004
[6]
Albelda.Pulmonarygenetics , genomics , and gene therapy. Steven M. Chest . 2002
[7]
Cilomilast,a selective phosphodiesterase-4inhibitor for treatment of paitents with chronic obstructive pulmonary disease:a randomized,dose-ranging study. Compton CH,Gubb J,Nie manR,et al. The Lancet . 2001
[8]
The global burden of disease, 1990-2020. Lopez AD,Murray CC. Nature Medicine . 1998
[9]
Oxidative stress and lung inflammation in airwaysdisease. MacNee W. European Journal of Pharmacology . 2001
[10]
Exhaled ethane,a marker of lipid peroxidation,is elevated in chronic obstructive pulmonary disease. Redline S,Kapur KV,Sanders HM,et al. American Journal of Respiratory and Critical Care Medicine . 2000